{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:47:49Z","timestamp":1792079269041,"version":"4.4.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T00:00:00Z","timestamp":1731196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T00:00:00Z","timestamp":1731196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008460","name":"National Center for Complementary and Integrative Health","doi-asserted-by":"publisher","award":["R01 AT009152"],"award-info":[{"award-number":["R01 AT009152"]}],"id":[{"id":"10.13039\/100008460","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["P30 ES005022"],"award-info":[{"award-number":["P30 ES005022"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-small cell lung cancer (NSCLC) accounts for 81% of lung cancer cases, among which over 47% presented with distant metastasis at the time of diagnosis. Despite the introduction of targeted therapy and immunotherapy, enhancing the survival rate and overcoming the development of resistance remain a big challenge. Thus, it is crucial to find potential new therapeutics and targets that can mitigate lung metastasis and investigate its effects on biomarkers, such as cellular metabolomics. In the current study, we investigated the role of cyproheptadine (CPH), an FDA-approved anti-histamine drug in lung metastasis in vitro and in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>CPH showed potent cytotoxicity on different lung cancer cell lines in vitro. Moreover, CPH decreased invasion and migration of LLC1 and A549 cells in Matrigel invasion transwell and plate scratch assays. The in vivo LLC1 syngeneic lung cancer model found decreased number of metastatic nodules on the surface of lungs of Setd7 KO mice compared to SETD7 WT. CPH treatment resulted in decreased growth of LLC1 subcutaneous tumors compared to untreated SETD7 WT. Finally, metabolomic study of tumor tissues showed rewiring of metabolomic pathways and downregulation of amino acids, such as arginine, serine, and glycine) in Setd7 KO and WT treated with CPH compared to untreated Setd7 WT mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings identify CPH as a potential therapeutic agent to block metastasis in advanced NSCLC and suggest SETD7 as a potential target for the prevention of lung metastasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11033-024-10033-6","type":"journal-article","created":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T03:00:09Z","timestamp":1731207609000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cyproheptadine inhibits in vitro and in vivo lung metastasis and drives metabolic rewiring"],"prefix":"10.1007","volume":"51","author":[{"given":"Ahmad","family":"Shannar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Shahid","family":"Sarwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parv Dushyant","family":"Dave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PoChung Jordan","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca Mary","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ah-Ng","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,10]]},"reference":[{"key":"10033_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35128","author":"TB Kratzer","year":"2024","unstructured":"Kratzer TB et al (2024) Lung cancer statistics, 2023. Cancer. https:\/\/doi.org\/10.1002\/cncr.35128","journal-title":"Cancer"},{"issue":"1","key":"10033_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3892\/mco.2014.410","volume":"3","author":"T Tamura","year":"2015","unstructured":"Tamura T et al (2015) Specific organ metastases and survival in metastatic non-small-cell lung cancer. Mol Clin Oncol 3(1):217\u2013221. https:\/\/doi.org\/10.3892\/mco.2014.410","journal-title":"Mol Clin Oncol"},{"issue":"4","key":"10033_CR3","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/mco2.105","volume":"2","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, Zhang T, Xu Q (2021) Therapeutic advances in non-small cell lung cancer: focus on clinical development of targeted therapy and immunotherapy. MedComm (2020) 2(4):692\u2013729. https:\/\/doi.org\/10.1002\/mco2.105","journal-title":"MedComm (2020)"},{"issue":"6","key":"10033_CR4","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nm.2169","volume":"16","author":"E Dolgin","year":"2010","unstructured":"Dolgin E (2010) Behind the paper: muzzling muscle spasticity. Nat Med 16(6):637\u2013637. https:\/\/doi.org\/10.1038\/nm.2169","journal-title":"Nat Med"},{"issue":"13","key":"10033_CR5","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1001\/jama.209.13.2054","volume":"209","author":"RE Noble","year":"1969","unstructured":"Noble RE (1969) Effect of cyproheptadine on appetite and weight gain in adults. J Am Med Assoc 209(13):2054\u20133000. https:\/\/doi.org\/10.1001\/jama.209.13.2054","journal-title":"J Am Med Assoc"},{"key":"10033_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1137-9","author":"YM Feng","year":"2015","unstructured":"Feng YM et al (2015) Cyproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase. BMC Cancer. https:\/\/doi.org\/10.1186\/s12885-015-1137-9","journal-title":"BMC Cancer"},{"issue":"6","key":"10033_CR7","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/ejh.12193","volume":"91","author":"J Li","year":"2013","unstructured":"Li J et al (2013) Cyproheptadine-induced myeloma cell apoptosis is associated with inhibition of the PI3K\/AKT signaling. Eur J Haematol 91(6):514\u2013521. https:\/\/doi.org\/10.1111\/ejh.12193","journal-title":"Eur J Haematol"},{"issue":"3","key":"10033_CR8","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1182\/blood-2008-02-142687","volume":"112","author":"XL Mao","year":"2008","unstructured":"Mao XL et al (2008) Cyproheptadine displays preclinical activity in myeloma and leukemia. Blood 112(3):760\u2013769. https:\/\/doi.org\/10.1182\/blood-2008-02-142687","journal-title":"Blood"},{"issue":"6","key":"10033_CR9","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/j.1365-2141.2009.07797.x","volume":"146","author":"L Paoluzzi","year":"2009","unstructured":"Paoluzzi L et al (2009) The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor. Br J Haematol 146(6):656\u2013659. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07797.x","journal-title":"Br J Haematol"},{"issue":"8","key":"10033_CR10","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1021\/acs.jmedchem.5b01732","volume":"59","author":"Y Takemoto","year":"2016","unstructured":"Takemoto Y et al (2016) Identification of cyproheptadine as an inhibitor of SET domain containing lysine methyltransferase 7\/9 (Set7\/9) that regulates estrogen-dependent transcription. J Med Chem 59(8):3650\u20133660. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01732","journal-title":"J Med Chem"},{"issue":"1","key":"10033_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.canlet.2015.09.018","volume":"370","author":"HY Hsieh","year":"2016","unstructured":"Hsieh HY et al (2016) Cyproheptadine exhibits antitumor activity in urothelial carcinoma cells by targeting GSK3beta to suppress mTOR and beta-catenin signaling pathways. Cancer Lett 370(1):56\u201365. https:\/\/doi.org\/10.1016\/j.canlet.2015.09.018","journal-title":"Cancer Lett"},{"key":"10033_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-01925-9","author":"YC Jou","year":"2021","unstructured":"Jou YC et al (2021) Cyproheptadine, an epigenetic modifier, exhibits anti-tumor activity by reversing the epigenetic silencing of IRF6 in urothelial carcinoma. Cancer Cell Int. https:\/\/doi.org\/10.1186\/s12935-021-01925-9","journal-title":"Cancer Cell Int"},{"key":"10033_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2012-007180","author":"YM Feng","year":"2012","unstructured":"Feng YM et al (2012) Unexpected remission of hepatocellular carcinoma (HCC) with lung metastasis to the combination therapy of thalidomide and cyproheptadine: report of two cases and a preliminary HCC cell line study. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2012-007180","journal-title":"BMJ Case Rep"},{"key":"10033_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.620212","author":"YM Feng","year":"2021","unstructured":"Feng YM et al (2021) Efficacy of cyproheptadine monotherapy in hepatocellular carcinoma with bone metastasis: a case report. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2021.620212","journal-title":"Front Oncol"},{"issue":"4","key":"10033_CR15","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1093\/jjco\/hyv007","volume":"45","author":"YM Feng","year":"2015","unstructured":"Feng YM et al (2015) Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients. Jpn J Clin Oncol 45(4):336\u2013342. https:\/\/doi.org\/10.1093\/jjco\/hyv007","journal-title":"Jpn J Clin Oncol"},{"key":"10033_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061414","author":"FL Monteiro","year":"2022","unstructured":"Monteiro FL, Williams C, Helguero LA (2022) A systematic review to define the multi-faceted role of lysine methyltransferase SETD7 in cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14061414","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10033_CR17","doi-asserted-by":"publisher","first-page":"4313","DOI":"10.1096\/fj.15-273540","volume":"29","author":"C Shen","year":"2015","unstructured":"Shen C et al (2015) SET7\/9 regulates cancer cell proliferation by influencing beta-catenin stability. FASEB J 29(10):4313\u20134323. https:\/\/doi.org\/10.1096\/fj.15-273540","journal-title":"FASEB J"},{"key":"10033_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154939","author":"YY Chen","year":"2016","unstructured":"Chen YY et al (2016) Increased expression of SETD7 promotes cell proliferation by regulating cell cycle and indicates poor prognosis in hepatocellular carcinoma. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0154939","journal-title":"PLoS ONE"},{"key":"10033_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.201700840","author":"C Wang","year":"2018","unstructured":"Wang C et al (2018) Histone methyltransferase Setd7 regulates Nrf2 signaling pathway by phenethyl isothiocyanate and ursolic acid in human prostate cancer cells. Mol Nutr Food Res. https:\/\/doi.org\/10.1002\/mnfr.201700840","journal-title":"Mol Nutr Food Res"},{"issue":"11","key":"10033_CR20","doi-asserted-by":"publisher","first-page":"6069","DOI":"10.21873\/anticanres.12957","volume":"38","author":"C Wang","year":"2018","unstructured":"Wang C et al (2018) Transcriptomic analysis of histone methyltransferase Setd7 knockdown and phenethyl isothiocyanate in human prostate cancer cells. J Anticancer Res 38(11):6069\u20136083. https:\/\/doi.org\/10.21873\/anticanres.12957","journal-title":"J Anticancer Res"},{"key":"10033_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061414","author":"FL Monteiro","year":"2022","unstructured":"Monteiro FL, Williams C, Helguero LA (2022) A systematic review to define the multi-faceted role of lysine methyltransferase SETD7 in cancer. Cancers. https:\/\/doi.org\/10.3390\/cancers14061414","journal-title":"Cancers"},{"key":"10033_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.bbrc.2021.07.086","volume":"572","author":"A Daks","year":"2021","unstructured":"Daks A et al (2021) Set7\/9 controls proliferation and genotoxic drug resistance of NSCLC cells. Biochem Biophys Res Commun 572:41\u201348. https:\/\/doi.org\/10.1016\/j.bbrc.2021.07.086","journal-title":"Biochem Biophys Res Commun"},{"issue":"28","key":"10033_CR23","doi-asserted-by":"publisher","first-page":"25843","DOI":"10.18632\/oncotarget.4584","volume":"6","author":"L Lezina","year":"2015","unstructured":"Lezina L et al (2015) KMT Set7\/9 affects genotoxic stress response via the Mdm2 axis. Oncotarget 6(28):25843\u201325855. https:\/\/doi.org\/10.18632\/oncotarget.4584","journal-title":"Oncotarget"},{"issue":"12","key":"10033_CR24","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1038\/cdd.2014.108","volume":"21","author":"L Lezina","year":"2014","unstructured":"Lezina L et al (2014) KMTase Set7\/9 is a critical regulator of E2F1 activity upon genotoxic stress. Cell Death Differ 21(12):1889\u20131899. https:\/\/doi.org\/10.1038\/cdd.2014.108","journal-title":"Cell Death Differ"},{"issue":"1","key":"10033_CR25","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.molcel.2010.06.006","volume":"39","author":"H Kontaki","year":"2010","unstructured":"Kontaki H, Talianidis I (2010) Lysine methylation regulates E2F1-induced cell death. Mol Cell 39(1):152\u2013160. https:\/\/doi.org\/10.1016\/j.molcel.2010.06.006","journal-title":"Mol Cell"},{"key":"10033_CR26","doi-asserted-by":"publisher","unstructured":"de Albuquerque Almeida Batista I, Helguero LA (2018) Biological processes and signal transduction pathways regulated by the protein methyltransferase SETD7 and their significance in cancer. Signal Transduct Target Ther 3(1):19. https:\/\/doi.org\/10.1038\/s41392-018-0017-6","DOI":"10.1038\/s41392-018-0017-6"},{"issue":"4","key":"10033_CR27","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.molcel.2011.08.006","volume":"43","author":"B Lehnertz","year":"2011","unstructured":"Lehnertz B et al (2011) p53-dependent transcription and tumor suppression are not affected in Set7\/9-deficient mice. Mol Cell 43(4):673\u2013680. https:\/\/doi.org\/10.1016\/j.molcel.2011.08.006","journal-title":"Mol Cell"},{"issue":"5","key":"10033_CR28","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1093\/carcin\/bgad024","volume":"44","author":"MS Sarwar","year":"2023","unstructured":"Sarwar MS et al (2023) The environmental carcinogen benzo[a]pyrene regulates epigenetic reprogramming and metabolic rewiring in a two-stage mouse skin carcinogenesis model. Carcinogenesis 44(5):436\u2013449. https:\/\/doi.org\/10.1093\/carcin\/bgad024","journal-title":"Carcinogenesis"},{"key":"10033_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175866","volume":"953","author":"MS Sarwar","year":"2023","unstructured":"Sarwar MS et al (2023) Metabolic rewiring and epigenetic reprogramming in leptin receptor-deficient db\/db diabetic nephropathy mice. Eur J Pharmacol 953:175866. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175866","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10033_CR30","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/carcin\/bgae009","volume":"45","author":"MS Sarwar","year":"2024","unstructured":"Sarwar MS et al (2024) Triterpenoid ursolic acid regulates the environmental carcinogen benzo[a]pyrene-driven epigenetic and metabolic alterations in SKH-1 hairless mice for skin cancer interception. Carcinogenesis 45(5):288\u2013299. https:\/\/doi.org\/10.1093\/carcin\/bgae009","journal-title":"Carcinogenesis"},{"key":"10033_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2350-2","author":"WZ Si","year":"2020","unstructured":"Si WZ et al (2020) SET7\/9 promotes multiple malignant processes in breast cancer development via RUNX2 activation and is negatively regulated by TRIM21. Cell Death Dis. https:\/\/doi.org\/10.1038\/s41419-020-2350-2","journal-title":"Cell Death Dis"},{"key":"10033_CR32","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.15690","author":"L Fu","year":"2016","unstructured":"Fu L et al (2016) Set7 mediated Gli3 methylation plays a positive role in the activation of Sonic Hedgehog pathway in mammals. Elife. https:\/\/doi.org\/10.7554\/eLife.15690","journal-title":"Elife"},{"issue":"1","key":"10033_CR33","doi-asserted-by":"publisher","first-page":"10347","DOI":"10.1038\/ncomms10347","volume":"7","author":"Y Kim","year":"2016","unstructured":"Kim Y et al (2016) Methylation-dependent regulation of HIF-1\u03b1 stability restricts retinal and tumour angiogenesis. Nat Commun 7(1):10347. https:\/\/doi.org\/10.1038\/ncomms10347","journal-title":"Nat Commun"},{"issue":"9","key":"10033_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113003","volume":"42","author":"CY Chiang","year":"2023","unstructured":"Chiang CY et al (2023) Methylation of KRAS by SETD7 promotes KRAS degradation in non-small cell lung cancer. Cell Rep 42(9):113003. https:\/\/doi.org\/10.1016\/j.celrep.2023.113003","journal-title":"Cell Rep"},{"issue":"18","key":"10033_CR35","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.1016\/j.bmc.2016.07.024","volume":"24","author":"T Fujiwara","year":"2016","unstructured":"Fujiwara T et al (2016) Steric structure-activity relationship of cyproheptadine derivatives as inhibitors of histone methyltransferase Set7\/9. Bioorg Med Chem 24(18):4318\u20134323. https:\/\/doi.org\/10.1016\/j.bmc.2016.07.024","journal-title":"Bioorg Med Chem"},{"issue":"15","key":"10033_CR36","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1002\/cmdc.201800233","volume":"13","author":"T Hirano","year":"2018","unstructured":"Hirano T et al (2018) Development of novel inhibitors for histone methyltransferase SET7\/9 based on cyproheptadine. ChemMedChem 13(15):1530\u20131540. https:\/\/doi.org\/10.1002\/cmdc.201800233","journal-title":"ChemMedChem"},{"issue":"8","key":"10033_CR37","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1016\/j.bmc.2018.02.016","volume":"26","author":"JM Rohde","year":"2018","unstructured":"Rohde JM et al (2018) Discovery and optimization of piperazine-1-thiourea-based human phosphoglycerate dehydrogenase inhibitors. Bioorg Med Chem 26(8):1727\u20131739. https:\/\/doi.org\/10.1016\/j.bmc.2018.02.016","journal-title":"Bioorg Med Chem"},{"key":"10033_CR38","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12885-015-1137-9","volume":"15","author":"YM Feng","year":"2015","unstructured":"Feng YM et al (2015) Cyproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase. BMC Cancer 15:134. https:\/\/doi.org\/10.1186\/s12885-015-1137-9","journal-title":"BMC Cancer"},{"issue":"1","key":"10033_CR39","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12935-021-01925-9","volume":"21","author":"YC Jou","year":"2021","unstructured":"Jou YC et al (2021) Cyproheptadine, an epigenetic modifier, exhibits anti-tumor activity by reversing the epigenetic silencing of IRF6 in urothelial carcinoma. Cancer Cell Int 21(1):226. https:\/\/doi.org\/10.1186\/s12935-021-01925-9","journal-title":"Cancer Cell Int"},{"key":"10033_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.semcancer.2022.10.006","volume":"87","author":"M Castaneda","year":"2022","unstructured":"Castaneda M et al (2022) Mechanisms of cancer metastasis. Semin Cancer Biol 87:17\u201331. https:\/\/doi.org\/10.1016\/j.semcancer.2022.10.006","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"10033_CR41","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41392-023-01528-y","volume":"8","author":"R Liu","year":"2023","unstructured":"Liu R et al (2023) Methylation across the central dogma in health and diseases: new therapeutic strategies. Signal Transduct Target Ther 8(1):310. https:\/\/doi.org\/10.1038\/s41392-023-01528-y","journal-title":"Signal Transduct Target Ther"},{"issue":"47","key":"10033_CR42","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1038\/s41388-023-02868-3","volume":"42","author":"B Karno","year":"2023","unstructured":"Karno B, Edwards DN, Chen J (2023) Metabolic control of cancer metastasis: role of amino acids at secondary organ sites. Oncogene 42(47):3447\u20133456. https:\/\/doi.org\/10.1038\/s41388-023-02868-3","journal-title":"Oncogene"},{"issue":"2","key":"10033_CR43","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.molcel.2020.11.027","volume":"81","author":"G Rinaldi","year":"2021","unstructured":"Rinaldi G et al (2021) In vivo evidence for serine biosynthesis-defined sensitivity of lung metastasis, but not of primary breast tumors, to mTORC1 inhibition. Mol Cell 81(2):386-397.e7. https:\/\/doi.org\/10.1016\/j.molcel.2020.11.027","journal-title":"Mol Cell"},{"issue":"1","key":"10033_CR44","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1038\/s41467-022-30363-y","volume":"13","author":"N Kiweler","year":"2022","unstructured":"Kiweler N et al (2022) Mitochondria preserve an autarkic one-carbon cycle to confer growth-independent cancer cell migration and metastasis. Nat Commun 13(1):2699. https:\/\/doi.org\/10.1038\/s41467-022-30363-y","journal-title":"Nat Commun"},{"issue":"2","key":"10033_CR45","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/cam4.4446","volume":"11","author":"S Yao","year":"2022","unstructured":"Yao S et al (2022) Phase 1 trial of ADI-PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors. Cancer Med 11(2):340\u2013347. https:\/\/doi.org\/10.1002\/cam4.4446","journal-title":"Cancer Med"},{"key":"10033_CR46","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2004761","author":"F Qiu","year":"2014","unstructured":"Qiu F et al (2014) Arginine starvation impairs mitochondrial respiratory function in ASS1-deficient breast cancer cells. Sci Signal. https:\/\/doi.org\/10.1126\/scisignal.2004761","journal-title":"Sci Signal"},{"issue":"6","key":"10033_CR47","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s11307-013-0655-6","volume":"15","author":"L Stelter","year":"2013","unstructured":"Stelter L et al (2013) Evaluation of arginine deiminase treatment in melanoma xenografts using (18)F-FLT PET. Mol Imaging Biol 15(6):768\u2013775. https:\/\/doi.org\/10.1007\/s11307-013-0655-6","journal-title":"Mol Imaging Biol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-10033-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-024-10033-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-10033-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T23:46:52Z","timestamp":1738712812000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-024-10033-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,10]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10033"],"URL":"https:\/\/doi.org\/10.1007\/s11033-024-10033-6","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,10]]},"assertion":[{"value":"31 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal use procedures were in accordance with the NIH (National Institutes of Health) Guide for the Care and Use of Laboratory Animals and were approved by the Rutgers Institutional Animal Care and Use Committee (IACUC).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"1139"}}